the 2nd edition of consensus statements for the diagnosis and management of intestinal behet’s disease indication of anti-tnfα monoclonal antibodies.pdfVIP

J Gastroenterol (2014) 49:156–162 DOI 10.1007/s00535-013-0872-4 RAPID COMMUNICATION The 2nd edition of consensus statements for the diagnosis and management of intestinal Behc¸et’s disease: indication of anti-TNFa monoclonal antibodies Tadakazu Hisamatsu • Fumiaki Ueno • Takayuki Matsumoto • Kiyonori Kobayashi • Kazutaka Koganei • Reiko Kunisaki • Fumihito Hirai • Masakazu Nagahori • Mitsunobu Matsushita • Kenji Kobayashi • Mitsumasa Kishimoto • Mitsuhiro Takeno • Masanori Tanaka • Nagamu Inoue • Toshifumi Hibi Received: 4 July 2013 / Accepted: 6 August 2013 / Published online: 18 August 2013 The Author(s) 2013. This article is published with open access at S Abstract discussion, which rated clinical statements on a nine-point Background Clinical evidence regarding intestinal Be- scale. After the first round of ratings, a panelist meeting hc¸et’s disease (BD) management is lacking and intestinal discussed areas of disagreement and clarified areas of lesions are a poor prognostic factor. In 2007, the Japan uncertainty. The list of clinical statements was revised after consensus statement for diagnosis and management of the panelist meeting and a second round of ratings was intestinal BD was developed. Recently, the efficacy of anti- conducted. tumor necrosis factor (TNF)a monoclonal antibodies Results Fifteen relevant articles were selected. Based on (mAbs), and infliximab (IFX) was reported and ada- the first edition consensus statement, improved clinical limumab (ADA) was approved for intestinal BD in Japan. statements regarding indications for anti-TNFa mAbs use This study renewed consensus-based practice guidelines were develop